Innovative blood loss treatment awarded
First published 10 September 2012
A James Cook University researcher who invented a treatment that helps resuscitate a patient following massive blood loss has won the best-of-the-best study at the Resuscitation Science Symposium at the annual American Heart Association.
Professor Geoffrey Dobson from the Heart and Trauma Research Laboratory in JCU’s Physiology and Pharmacology department, and international collaborators will receive the award at a special research meeting in Los Angeles in November.
Hayley Letson, Professor Dobson’s PhD candidate and research associate at JCU, will receive the Young Investigator Award at the same meeting.
Professor Dobson said the team had won the best-of-the-best awards, which are judged by a leading panel of experts from trauma and military fields, three years running, as well as two Young Investigator awards.
Professor Dobson, who is also Chief Scientific Officer of Hibernation Therapeutics, a spin-off biotechnology company from JCU, said his invention would have life-changing effects in battlefield situations.
“For the first time in the history of fluid resuscitation, we may have the capability to develop ‘one solution’ for surgical stabilisation of combat casualties suffering catastrophic blood loss with or without traumatic brain injury,” he said.
“At the moment, combat medics or emergency first responder teams have a limited range of pharmacological options for rescuing and stabilising the heart of soldiers or civilians following massive haemorrhage in the first few minutes of injury.”
The treatment will help enable a casualty to be rapidly evacuated to surgical care.
Professor Dobson and his team at JCU and Hibernation Therapeutics are working with the US Military and the US Naval Medical Research Center to develop two products.
One is a small volume adenocaine and magnesium resuscitation fluid for severe blood loss to be administered on location, enabling a casualty to be stabilised for evacuation for surgical care.
A second is an injectable product which aims to arrest the whole body and brain for 10 to 20 minutes after catastrophic blood loss for immediate transport to a trauma facility.
Professor Dobson said the goal was to have two US Food and Drug Administration-approved products from “bench to battlefield” in five years.
Professor Dobson said he was invited by the US Navy to attend the 2012 Fort Lauderdale Military Health System Research Symposium in August, and is working with leaders as part of an evolving acquisition strategy.
“At Fort Lauderdale, I was invited to attend the TTCP-TP12 - combat casualty care - to update on the adenocaine fluid resuscitation developments.”
Professor Dobson said Kaylene Williams from the Australian Defence Force (Combat Casualty Care), Professor Michael Reade, newly appointed Chair of Military Surgery and Medicine at The University of Queensland and the Minister of Defence Stephen Smith were very supportive of the team’s work.
In 2011 Dr Dobson was elected as Fellow of the American Heart Association for scientific and professional accomplishments and volunteer leadership and service to heart awareness
For interviews, contact Professor Geoff Dobson on (07) 4781 4097 or 0407 550 235, email email@example.com
JCU Media contact: Caroline Kaurila (07) 4781 4586 or 0437 028 175